Neuphoria Therapeutics Inc.
	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014	Q4-CY2013
Balance Sheet Date			2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30
Fiscal Period			Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024
Total Revenue			(13,267$)	15,000,000$	662,715$
Cost Of Revenue			0$	0$	0$
Gross Profit			(13,267$)	15,000,000$	662,715$
Gross Margin			100.00%	100.00%	100.00%
Operating Expenses			5,821,779$	3,022,807$	4,366,226$	3,567,727$	5,477,876$	2,394,031$	4,552,862$	5,467,607$
Operating Income			(5,835,046$)	11,977,193$	(3,703,511$)	(3,567,727$)	(5,477,876$)	(2,394,031$)	(4,552,862$)	(5,467,607$)
Other Income			(3,402,259$)	(808,959$)	1,741,156$	2,594,657$	2,730,407$	(420,349$)	(91,072$)	(126,193$)
Interest Income			87,046$	12,741$	30,615$	36,096$	26,327$	52,615$	54,716$	86,439$
Interest Expenses
Income Before Tax			(9,150,259$)	11,180,975$	(1,931,740$)	(936,974$)	(2,721,142$)	(2,761,765$)	(4,589,218$)	(5,507,361$)
Tax Expenses			(266,602$)	(81,186$)	11,609$	(132,187$)	(34,116$)	16,383$	(34,794$)	(34,793$)
Income from Continuing Operations			(8,883,657$)	11,262,161$	(1,943,349$)	(804,787$)	(2,687,026$)	(2,778,148$)	(4,554,424$)	(5,472,568$)
Income from Discontinued Operations
Consolidated Income			(8,883,657$)	11,262,161$	(1,943,349$)	(804,787$)	(2,687,026$)	(2,778,148$)	(4,554,424$)	(5,472,568$)
Net Income			(8,883,657$)	11,262,161$	(1,943,349$)	(804,787$)	(2,687,026$)	(2,778,148$)	(4,554,424$)	(5,472,568$)
Profit Margin			66,960.56%	75.08%	(293.24%)
Earnings to Minority
Earnings to Common Shareholders			(8,883,657$)	11,262,161$	(1,943,349$)	(804,787$)	(2,687,026$)	(2,778,148$)	(4,554,424$)	(5,472,568$)
Earnings Per Share, Basic			0.00$	6.55$	(1.23$)	0.00$	0.00$	(2.83$)	(5.31$)	0.00$
Earnings Per Share, Diluted			0.00$	6.55$	(1.23$)	0.00$	0.00$	(2.83$)	(5.31$)	0.00$
Average Shares, Basic			-2,804,943,364	1,719,073	1,575,244	2,808,140,743	-1,494,504,439	981,040	857,264	1,495,995,035
Average Shares, Diluted			-2,804,943,364	1,719,073	1,575,244	2,808,140,743	-1,494,504,439	981,040	857,264	1,495,995,035
EBIT			(9,150,259$)	11,180,975$	(1,931,740$)	(936,974$)	(2,721,142$)	(2,761,765$)	(4,589,218$)	(5,507,361$)
EBITDA			(8,984,634$)	11,346,406$	(1,765,619$)	(771,261$)	(2,555,457$)	(2,596,062$)	(4,423,524$)	(5,341,452$)

• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation